About Us
Driven by Science, Dedicated to Patients
Grounded in rigorous academic research and driven by a deep sense of urgency, Endios Bio is on a mission to bring hope to people living with ALS and other neurological diseases.
Our Story
A Discovery Worth Building Around
Courtesy Angela Branson and CU Boulder
Endios Bio was founded to solve one of the most devastating challenges in neurology: ALS. Despite decades of research, ALS remains incurable—with most patients surviving only 2 to 5 years after diagnosis. The team behind Endios believed the answer might lie not in revisiting old targets, but in uncovering new ones.
That breakthrough came through the work of Dr. Alexandra Whiteley, a faculty member at the University of Colorado Boulder. Her lab discovered that a retrovirus-derived gene called PEG10 plays a previously unrecognized, toxic role in ALS and neurodevelopmental disorders like Angelman syndrome.
The significance was clear: PEG10 was not just a marker—it was a driver. And no one was targeting it.
This insight led Wendy Overton, Endios Bio’s CEO & co-founder, to join CU Boulder as an entrepreneur-in-residence with CU Boulder’s Embark Deep Tech Startup Creator, teaming up with Dr. Whiteley to turn this discovery into a therapy that could change the trajectory of ALS.
Our Mission
Science With Purpose. Therapies With Impact.
To develop first-in-class therapeutics that target unexplored biological mechanisms in neurodegeneration—beginning with PEG10 in ALS.
We believe the future of neurological treatment lies in:
Our Founders
Where Breakthrough Science Meets Bold Leadership
Endios Bio was founded by a team of scientists and entrepreneurs driven to translate breakthrough academic research into real-world therapies. With deep roots in molecular biology and early-stage biotech development, our leadership combines scientific innovation with the operational focus needed to bring new treatments to patients faster.
Wendy Overton, MBA
Chief Executive Officer
Ms. Overton brings over a decade of experience with early-stage startups and bringing innovation to market. A graduate of CU’s Embark and Ascent Deep Tech Accelerator programs, she guides Endios’ business development, fundraising, and strategic partnerships.
Alexandra Whiteley, PhD
Chief Scientific Officer
As a molecular biologist and Assistant Professor at the University of Colorado Boulder, Dr. Whiteley’s research focuses on protein homeostasis and its role in neurodegeneration. Her lab was the first to identify PEG10’s involvement in ALS pathology, paving the way for a new generation of therapeutic strategies.
Our Values
The Principles That Power Our Progress.
We’re guided by bold science, integrity, and urgency. At every step, our values push us to move faster, think deeper, and stay focused on what matters most: patients.
Innovation
We pursue bold ideas grounded in rigorous science.
Urgency
We work fast because patients can’t wait.
Integrity
We follow the data and communicate transparently.
Collaboration
We bridge the gap between labs, clinics, and communities.